Multi-analyte analysis of cytokines that predict outcomes in patients with hepatocellular carcinoma treated with radiotherapy

Table 5 Univariate and multivariate analyses of clinical factors or cytokines for failure-free survival - extrahepatic failure-free survival

	Univariate		Multivariate
	P value	RR (95%CI)	P value	RR (95%CI)
Sex	0.153	2.043 (0.768-5.438)
Age	0.502	0.987 (0.951-1.025)
Stage	0.196	1.562 (0.795-3.070)
BCLC	0.782	0.942 (0.615-1.441)
Size	0.830	1.010 (0.926-1.101)
PVT	0.988	0.994 (0.465-2.125)
LN metastasis	0.936	0.952 (0.289-3.141)
Multiplicity	0.622	1.197 (0.586-2.448)
AFP	0.034	1.001 (1.000-1.003)	0.034	1.001 (1.000-1.003)
PIVKA-II	0.449	1.016 (0.976-1.057)
Pre-RT treatment	0.878	1.057 (0.520-2.147)
Baseline IL-1	0.725	1.005 (0.977-1.034)
Baseline IL-6	0.529	1.002 (0.996-1.007)
Baseline IL-8	0.546	1.001 (0.999-1.003)
Baseline IL-10	0.309	1.062 (0.946-1.193)
Baseline IL-12	0.726	1.009 (0.962-1.058)
Baseline TNF-α	0.956	1.002 (0.942-1.066)

Age, size, AFP, PIVKA-II, and baseline cytokine levels were analyzed as continuous variables using the Cox hazard ratio model. BCLC: Barcelona Clinic Liver Cancer; PVT: Portal vein thrombosis; LN: Lymph node; AFP: α-fetoprotein; PIVKA-II: Prothrombin induced by vitamin K absence-II; RT: Radiotherapy; IL: Interleukin; TNF: Tumor necrosis factor.